ProCE Banner Activity

FINCH 1: 52-Wk Results of Filgotinib in Patients With Rheumatoid Arthritis With Inadequate Response to Methotrexate

Slideset Download
Conference Coverage
Efficacy of add-on therapy with JAK1 inhibitor filgotinib sustained through Week 52 with no new safety signals in patients with rheumatoid arthritis and inadequate response to methotrexate.

Released: July 13, 2020

Expiration: July 12, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Gilead Sciences, Inc.